> The FDA has approved BioMarin Pharmaceutical's disintegrating tablet form of Orapred for pediatric acute asthma. Report
> The FDA has rejected a bid by Akzo Nobel's Organon to market tibolone to women with menopausal symptoms. Report
> India's national strategy for biotechnology has, so far, failed to get past a draft version. Report
> Genentech says that a Phase IIIb trial of Lucentis met its primary endpoint of preventing vision loss. Report
> Generex Biotechnology has raised $13.5 million in a private placement. Release
> OSI Pharmaceuticals announced yesterday that data from a mid-stage trial showed that Macugen prevented a type of vision loss better than a placebo. Report
> The FDA has approved Ranbaxy's application to produce a generic version of Bioglan's Adoxa. Report
> The FDA has given final approval to Watson Pharmaceuticals' generic version of the birth control medicine Levlite. Report
And Finally… Japan's birth rate continues to decline, presenting a series of challenges as the population shrinks. Article